In-silico studies for design and development of inhibitor against Covid-19
DOI:
https://doi.org/10.56511/JIPBS.2021.v8.i01.pp14-24Abstract
Aim: The Covid-19 pandemic as declared by WHO, reported its first case in Wuhan, Hunei province, China. The infections have now been widespread and as of 30th March 2020, 6,93,224 infection cases and 33,106 deaths have been reported worldwide. This is an international concern related to public health. Several research studies are being carried on around the world to amid the crises. Various treatment and prevention hypothesis regarding vaccine development, repurposing of drugs along with development of new chemical entities are under investigation. Covid-19 is a virus from the coronavirus family of viruses of beta genus. It has similarity with the SARS-CoV which was reported earlier. We plan to propose a scaffold for designing peptide derived specific inhibitor against Covid-19.Method: Our strategy involves designing a peptide inhibitor that will interact with RBM of the SARS-CoV-2 and inhibit its entry inside the cell. We utilised online peptide designing platform called rosetta, Autodock Vena a computer aided drug designing software and Schrodinger’s Drug Discovery Suite Result: We propose a peptide based on the sequence of human ACE2 which interacts strongly with RBM of the SARS-CoV-2. Interested readers can utilise the sequence for further modification of the peptide sequence to convert it into a peptidomimetic.Conclusion: Receptor binding motif of SARS-CoV-2 has stronger affinity towards the derived peptide so as to terminate the infection cascade. The proposed peptide can surely be used as scaffold for designing more active agents.
Keywords:
Computer Aided Drug Design, Covid-19, Peptides, ACE 2, Spike ProteinDownloads
References
Andersen KG, Rambaut A, Lipkin WI, Holmes EC and Garry RF: The proximal origin of SARS-CoV-2. Nature Medicine 2020; 1-3.
Adhikari SP, Meng S, Wu Y, Mao Y, Ye R, Wang Q, Sun C, Sylvia S, Rozelle S and Raat H: A Literature Review of 2019 Novel Coronavirus during the Early Outbreak Period: Epidemiology, Causes, Clinical Manifestation and Diagnosis. Prevention and Control. Infection Disease Poverty. 2020; 1 – 12.
WMCH, Wuhan, Municipal Health and Health Commissi on’s Briefing on the Current Pneumonia Epidemic Situation in Our City. 2020; http://wjw.wuhan.gov.cn/front/ web/showDetail/ 2019123108989.Accessed.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY and Wong JY: Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus – Infected Pneumonia. New England Journal of Medicine 2020; 1199 – 1207.
CDC. 2019 Novel coronavirus, Wuhan, China. 2019; h ttps://www.cdc.gov/corona virus/ 2019-nCoV/summary.html. Accessed.
WHO. Novel Coronavirus-China. 2020. 2020; https://www . cdc.gov/coronavirus/2019nCoV/summary.html.
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM and Neuman BW: The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-NCoV and Naming It SARS-CoV-2. Natural Microbiology 2020; 5: 536 – 544.
Walls AC, Park YJ, M. Tortorici MA, Wall A, McGuire AT and Veesler D: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020; 1-34.
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS and Mclellan JS: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367: 1260 – 1263.
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W and Wang M: Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARSCoV-2 infection in vitro. Cell Discovery 2020; 186: 1 – 4.
Bagdonaite I and Wandall HH: Global aspects of viral glycosylation. Glycobiology 2018; 28: 443 – 467.
Cui J, Li F and Shi ZL: Origin and Evolution of Pathogenic Coronaviruses. Nature Review Microbiology 2019: 17: 181 – 192.
Almazán F, Sola I, Zuñiga S, Marquez-Jurado S, Morales L, Becares M and Enjuanes L: Coronavirus reverse genetic systems: Infectious clones and replicons. Virus Research 2014; 189: 262 – 270.
Wan Y, Shang J, Graham R, R. Baric RS and Li F: Receptor Recognition by Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS. Journal of Virology 2020; 94: 1-9.
Huang L: Novel Peptide Inhibitors of Angiotensin-converting Enzyme 2. Journal of Bio-Chemistry. 2003; 278: 15532 – 15540.
Sedan Y, Marcu O, Lyskov S and Schueler-Furman O: Peptiderive server: derive peptide inhibitors from proteinprotein interactions. Nucleic Acids Research 2016; 44: 536 – 541.
London N, Raveh B, Movshovitz-Attias D and SchuelerFurman O: can self-inhibitory peptides be derived from the interfaces of globular protein-protein interactions? Proteins: Structure, Function, and Bioinformatics. 2010; 78: 3140 – 3149.
Lyskov S: Serverification of Molecular Modeling Applications: The Rosetta Online Server That Includes Everyone (ROSIE). PLoS ONE 2013; 8: 1-11.
Koes DR, Baumgartner MP and Camacho CJ: Lessons Learned in Empirical Scoring with smina from the CSAR 2011 Benchmarking Exercise. Journal of Chemical Information and Modelling 2013; 53(8):1893 – 1904.
Brooks BR: AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading Journal of computational chemistry 2009; 30: 1545 – 1614.
Morris G and Huey R: AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry 2009; 30: 2785 – 2791.
Published
How to Cite
Issue
Section
Copyright (c) 2021 Akshata R. Pahelkar, Pritam V. Bagwe, Khushboo Maurya, Nikhil R. Pahelkar, Shreerang V. Joshi, Vikas N. Telvekar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at